Centessa Pharmaceuticals 10-Q/A Report: Key Trading Amendments & Executive Plans

Here are the key insights and information extracted from the provided financial report section:

1. Company Overview:

• Name: Centessa Pharmaceuticals plc
• CIK: 0001847903
• NASDAQ Symbol: CNTA
• Ordinary Shares: Nominal value of £0.002 per share.

2. Filing Details:

• Filing Type: Amendment No. 1 on Form 10-Q/A.
• Original Filing Date: November 12, 2024.
• Fiscal Quarter Ended: September 30, 2024.
• Purpose of Amendment: To add Rule 10b5-1 trading arrangements omitted from the original filing and to include new certifications from the CEO and CFO.

3. Trading Arrangements:

• Rule 10b5-1 Plans were adopted by the following executives during the quarter:
• • Karen Anderson (Chief People Officer)
  • Shares Available for Sale: 146,971
  • Plan Effective From: December 13, 2024
  • Expiration Date: August 15, 2025
  • Tia Bush (Chief Technology and Quality Officer)
  • Shares Available for Sale: 203,216
  • Plan Effective From: December 10, 2024
  • Expiration Date: December 15, 2025
  • Iqbal Hussain (General Counsel and Corporate Secretary)
  • Shares Available for Sale: 183,705
  • Plan Effective From: December 14, 2024
  • Expiration Date: December 15, 2025

4. Terminated Trading Arrangement:

• Harris Rotman (former Senior VP of Regulatory Affairs)
• • Plan Termination Date: August 1, 2024
  • Shares Sold Under Plan: 41,751 (previously adopted on June 20, 2023)

5. Additional Information:

• The Company confirms that no financial statements are included in the amendment and that existing information from the Original Filing remains unchanged, aside from the amendments specifically mentioned.

This document primarily addresses compliance with trading regulations and updates on executive trading plans, which are critical for transparency and investor awareness regarding insider trading activities.